CL2020002943A1 - Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020 - Google Patents
Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020Info
- Publication number
- CL2020002943A1 CL2020002943A1 CL2020002943A CL2020002943A CL2020002943A1 CL 2020002943 A1 CL2020002943 A1 CL 2020002943A1 CL 2020002943 A CL2020002943 A CL 2020002943A CL 2020002943 A CL2020002943 A CL 2020002943A CL 2020002943 A1 CL2020002943 A1 CL 2020002943A1
- Authority
- CL
- Chile
- Prior art keywords
- application
- inhibitors
- methods
- mcl
- macrocyclic
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102220480121 H/ACA ribonucleoprotein complex subunit DKC1_R10A_mutation Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente divulgación proporciona compuestos de la Fórmula en donde A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X e Y tienen cualquiera de los valores definidos en la memoria descriptiva, y sales aceptables desde el punto de vista farmacéutico de estos, que son útiles como agentes en el tratamiento de enfermedades y afecciones, incluido el cáncer. También se proporcionan composiciones farmacéuticas que comprenden compuestos de la Fórmula (I).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545853P | 2017-08-15 | 2017-08-15 | |
| US201762555475P | 2017-09-07 | 2017-09-07 | |
| US201862692663P | 2018-06-30 | 2018-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002943A1 true CL2020002943A1 (es) | 2021-03-12 |
Family
ID=65362347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000363A CL2020000363A1 (es) | 2017-08-15 | 2020-02-12 | Inhibidores macrocíclicos de mcl-1 y métodos de uso. |
| CL2020002943A CL2020002943A1 (es) | 2017-08-15 | 2020-11-12 | Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000363A CL2020000363A1 (es) | 2017-08-15 | 2020-02-12 | Inhibidores macrocíclicos de mcl-1 y métodos de uso. |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US10676485B2 (es) |
| EP (2) | EP3652184A4 (es) |
| JP (1) | JP2020531433A (es) |
| KR (1) | KR20200041942A (es) |
| CN (1) | CN111818917A (es) |
| AU (1) | AU2018316620A1 (es) |
| BR (1) | BR112020003180A2 (es) |
| CA (1) | CA3073112A1 (es) |
| CL (2) | CL2020000363A1 (es) |
| CO (1) | CO2020002678A2 (es) |
| CR (1) | CR20200124A (es) |
| EC (1) | ECSP20018703A (es) |
| IL (1) | IL272681A (es) |
| MX (1) | MX2020001717A (es) |
| PE (1) | PE20200837A1 (es) |
| PH (1) | PH12020500327A1 (es) |
| RU (1) | RU2020110517A (es) |
| SG (2) | SG11202001182QA (es) |
| TW (1) | TW201920194A (es) |
| UA (1) | UA126586C2 (es) |
| UY (1) | UY37843A (es) |
| WO (1) | WO2019035911A1 (es) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11414390B2 (en) | 2017-09-07 | 2022-08-16 | Hutchison Medipharma Limited | Cycloolefin substituted heteroaromatic compounds and their use |
| US11957673B2 (en) | 2017-09-07 | 2024-04-16 | Augusta University Research Institute, Inc. | Specific AKT3 activator and uses thereof |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3668513B1 (en) | 2017-08-15 | 2021-11-10 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in treating blood disorders |
| AU2018317828A1 (en) * | 2017-08-15 | 2020-04-02 | AbbVie Deutschland GmbH & Co. KG | Macrocyclic MCL-1 inhibitors and methods of use |
| MX2020001719A (es) * | 2017-08-15 | 2020-11-06 | Abbvie Inc | Inhibidores macrocíclicos de mcl-1 y metodos de uso. |
| CR20200124A (es) * | 2017-08-15 | 2020-09-28 | Abbvie Inc | Inhibidores macrocíclicos de mcl-1 y métodos de uso |
| AU2020279979A1 (en) | 2019-05-20 | 2021-11-25 | Les Laboratoires Servier | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| JP2023553808A (ja) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| TWI861509B (zh) | 2021-06-11 | 2024-11-11 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗體藥物接合物之組合 |
| JP7900421B2 (ja) | 2021-06-11 | 2026-08-04 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ |
| IL317101A (en) | 2022-05-20 | 2025-01-01 | Novartis Ag | Antibody-drug conjugates of anticancer compounds and methods of using them |
| AR134424A1 (es) | 2023-11-22 | 2026-01-14 | Novartis Ag | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos |
| UY40985A (es) | 2023-11-22 | 2025-06-30 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009241469B2 (en) * | 2008-04-30 | 2015-05-07 | National Health Research Institutes | Fused bicyclic pyrimidine compounds as Aurora kinase inhibitors |
| FR3015483B1 (fr) | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JO3474B1 (ar) * | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| FR3037959B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037956B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037958B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3046792B1 (fr) | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CR20180499A (es) | 2016-04-22 | 2019-01-25 | Astrazeneca Ab | Inhibidores de mcl1 macrocicliclos para tratar el cancer |
| WO2018015526A1 (en) | 2016-07-22 | 2018-01-25 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof |
| TWI749091B (zh) | 2016-10-28 | 2021-12-11 | 法商施維雅藥廠 | 脂質體調配物 |
| WO2018126898A1 (zh) | 2017-01-05 | 2018-07-12 | 河南美泰宝生物制药有限公司 | 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用 |
| UY37560A (es) | 2017-01-06 | 2018-07-31 | Servier Lab | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta |
| MX2020001719A (es) * | 2017-08-15 | 2020-11-06 | Abbvie Inc | Inhibidores macrocíclicos de mcl-1 y metodos de uso. |
| CR20200124A (es) * | 2017-08-15 | 2020-09-28 | Abbvie Inc | Inhibidores macrocíclicos de mcl-1 y métodos de uso |
| AU2018317828A1 (en) * | 2017-08-15 | 2020-04-02 | AbbVie Deutschland GmbH & Co. KG | Macrocyclic MCL-1 inhibitors and methods of use |
| CN107573360B (zh) | 2017-10-27 | 2019-08-09 | 都创(上海)医药科技有限公司 | 一种多靶点小分子化合物s63845的制备方法 |
-
2018
- 2018-08-15 CR CR20200124A patent/CR20200124A/es unknown
- 2018-08-15 TW TW107128523A patent/TW201920194A/zh unknown
- 2018-08-15 AU AU2018316620A patent/AU2018316620A1/en not_active Abandoned
- 2018-08-15 CN CN201880066986.9A patent/CN111818917A/zh active Pending
- 2018-08-15 BR BR112020003180-1A patent/BR112020003180A2/pt not_active IP Right Cessation
- 2018-08-15 US US15/998,789 patent/US10676485B2/en active Active
- 2018-08-15 PE PE2020000240A patent/PE20200837A1/es unknown
- 2018-08-15 EP EP18846737.7A patent/EP3652184A4/en not_active Withdrawn
- 2018-08-15 MX MX2020001717A patent/MX2020001717A/es unknown
- 2018-08-15 JP JP2020508463A patent/JP2020531433A/ja active Pending
- 2018-08-15 RU RU2020110517A patent/RU2020110517A/ru unknown
- 2018-08-15 CA CA3073112A patent/CA3073112A1/en active Pending
- 2018-08-15 WO PCT/US2018/000180 patent/WO2019035911A1/en not_active Ceased
- 2018-08-15 UA UAA202001749A patent/UA126586C2/uk unknown
- 2018-08-15 SG SG11202001182QA patent/SG11202001182QA/en unknown
- 2018-08-15 UY UY0001037843A patent/UY37843A/es not_active Application Discontinuation
- 2018-08-15 KR KR1020207007568A patent/KR20200041942A/ko not_active Ceased
- 2018-08-15 SG SG10202106345VA patent/SG10202106345VA/en unknown
- 2018-08-15 EP EP21197248.4A patent/EP3988555A1/en active Pending
-
2020
- 2020-02-12 CL CL2020000363A patent/CL2020000363A1/es unknown
- 2020-02-13 PH PH12020500327A patent/PH12020500327A1/en unknown
- 2020-02-14 IL IL272681A patent/IL272681A/en unknown
- 2020-03-10 CO CONC2020/0002678A patent/CO2020002678A2/es unknown
- 2020-03-13 EC ECSENADI202018703A patent/ECSP20018703A/es unknown
- 2020-05-11 US US16/872,279 patent/US20200325153A1/en not_active Abandoned
- 2020-11-12 CL CL2020002943A patent/CL2020002943A1/es unknown
-
2022
- 2022-02-03 US US17/649,906 patent/US20230183261A1/en not_active Abandoned
-
2024
- 2024-02-29 US US18/592,020 patent/US20250092062A1/en not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11414390B2 (en) | 2017-09-07 | 2022-08-16 | Hutchison Medipharma Limited | Cycloolefin substituted heteroaromatic compounds and their use |
| US11957673B2 (en) | 2017-09-07 | 2024-04-16 | Augusta University Research Institute, Inc. | Specific AKT3 activator and uses thereof |
| US12234211B2 (en) | 2017-09-07 | 2025-02-25 | Hutchison Medipharma Limited | Cycloolefin substituted heteroaromatic compounds and their use |
| US12616690B2 (en) | 2017-09-07 | 2026-05-05 | Augusta University Research Institute, Inc. | Specific AKT3 activator and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020110517A (ru) | 2021-09-16 |
| SG10202106345VA (en) | 2021-07-29 |
| RU2020110517A3 (es) | 2022-03-23 |
| PE20200837A1 (es) | 2020-08-13 |
| AU2018316620A1 (en) | 2020-03-12 |
| UY37843A (es) | 2019-03-29 |
| CR20200124A (es) | 2020-09-28 |
| PH12020500327A1 (en) | 2020-10-12 |
| UA126586C2 (uk) | 2022-11-02 |
| CA3073112A1 (en) | 2019-02-21 |
| EP3652184A1 (en) | 2020-05-20 |
| SG11202001182QA (en) | 2020-03-30 |
| CL2020000363A1 (es) | 2020-06-12 |
| IL272681A (en) | 2020-03-31 |
| EP3652184A4 (en) | 2020-05-20 |
| JP2020531433A (ja) | 2020-11-05 |
| CO2020002678A2 (es) | 2020-08-10 |
| KR20200041942A (ko) | 2020-04-22 |
| WO2019035911A1 (en) | 2019-02-21 |
| US20250092062A1 (en) | 2025-03-20 |
| US10676485B2 (en) | 2020-06-09 |
| CN111818917A (zh) | 2020-10-23 |
| MX2020001717A (es) | 2020-10-08 |
| US20230183261A1 (en) | 2023-06-15 |
| BR112020003180A2 (pt) | 2020-09-15 |
| ECSP20018703A (es) | 2020-04-22 |
| TW201920194A (zh) | 2019-06-01 |
| US20190144465A1 (en) | 2019-05-16 |
| US20200325153A1 (en) | 2020-10-15 |
| EP3988555A1 (en) | 2022-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20018703A (es) | Inhibidores macrocíclicos de mcl-1 y métodos de uso | |
| MX2020001719A (es) | Inhibidores macrocíclicos de mcl-1 y metodos de uso. | |
| UY37842A (es) | Inhibidores de mcl-1 macrocíclicos y métodos de uso | |
| DOP2022000117A (es) | Inhibidores de kras g12c | |
| CO2018011064A2 (es) | Inhibidores de bromodominios | |
| MX2022010520A (es) | Macrociclos peptidicos contra acinetobacter baumannii. | |
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| MX2016011468A (es) | Inhibidores de calicreína plasmática humana. | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| CO2018004572A2 (es) | Inhibidores de calicreína plasmática humana | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| CY1121060T1 (el) | Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| EA201990766A1 (ru) | Индазольные соединения для применения при повреждениях сухожилий и/или связок | |
| MX389106B (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. |